Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Malignant Mesothelioma
NCT03531840Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in malignant mesothelioma, sponsored by National Cancer Institute. Started Jul 2018; status: completed.
02
Drugs
olaparib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT03531840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531840.